Leerink Partners Maintains Outperform on Nanobiotix, Raises Price Target to $46

Benzinga Newsdesk www.benzinga.com Positive 89.8%

Neg 0% Neu 0% Pos 89.8%

Leerink Partners analyst Jonathan Chang maintains Nanobiotix (NASDAQ:NBTX) with a Outperform and raises the price target from $37 to $46.